argenex SE $ARGX Shares Acquired by Candriam S.C.A.

Candriam S.C.A. boosted its position in shares of argenex SE (NASDAQ:ARGX) by 11.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 54,148 shares of the company’s stock after buying an additional 5,407 shares during the quarter. Candriam S.C.A.’s holdings in argenex were worth $39,542,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Oppenheimer & Co. Inc. raised its position in argenex by 2.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock worth $372,000 after acquiring an additional 12 shares in the last quarter. Valeo Financial Advisors LLC boosted its position in shares of argenex by 0.9% during the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after purchasing an additional 12 shares in the last quarter. CI Investments Inc. grew its stake in shares of argenex by 2.6% in the 4th quarter. CI Investments Inc. now owns 469 shares of the company’s stock worth $394,000 after purchasing an additional 12 shares during the last quarter. Allworth Financial LP grew its stake in shares of argenex by 12.7% in the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock worth $97,000 after purchasing an additional 13 shares during the last quarter. Finally, WPG Advisers LLC raised its holdings in shares of argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after purchasing an additional 13 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Trading Down 3.5%

ARGX stock opened at $877.62 on Friday. argenex SE has a one year low of $553.54 and a one year high of $953.58. The firm has a 50-day moving average of $853.70 and a two-hundred day moving average of $813.07. The firm has a market capitalization of $54.58 billion, a PE ratio of 39.07, a P/E/G ratio of 1.12 and a beta of 0.45.

argenex (NASDAQ:ARGX) last released its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The business had revenue of $1.31 billion for the quarter. On average, equities research analysts anticipate that argenex SE will post 26.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ARGX shares. Bank of America increased their target price on shares of argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Glj Research upgraded shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Guggenheim upped their price target on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a report on Friday, May 8th. HC Wainwright reiterated a “buy” rating and set a $940.00 price objective on shares of argenex in a research report on Thursday, June 25th. Finally, Wedbush reissued an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a research note on Thursday, June 11th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, argenex currently has an average rating of “Moderate Buy” and a consensus target price of $1,037.61.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.